Navigation Links
Callisto Reports on Second-Quarter 2007 Milestones
Date:8/19/2007

hetic molecule) of uroguanylin developed by Callisto scientists, and is proprietary to Callisto. Guanilib has been demonstrated to be superior to uroguanylin in its biological activity, protease stability and pH characteristics, and is currently undergoing pre-clinical animal studies as a treatment for gastrointestinal (GI) diseases and GI inflammation. Animal model data on Guanilib previously demonstrated anti-inflammatory activity in a number of mouse-models of ulcerative colitis, and the drug is currently being evaluated in animal models of GI disorders. Callisto plans to initiate clinical trials of Guanilib in early 2008.

About Atiprimod

Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and gastrointestinal diseases. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs in pre-clinical development for other significant health care markets, including gastrointestinal disorders. One of the Company's lead drug candidates, Atiprimod is presently in a Phase II clinical trial in advanced carcinoid cancer patients, a neuroendocrine tumor, and in a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Another anti-cancer drug, L-Annamycin, is being developed as a treatment for forms of relapsed or refractory ac
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Larry J. ... CVS ), will speak before the National Press Club ... discuss the company,s recent move to stop selling tobacco products ... the future of health. "Dramatic changes in our ... care providers and government," Merlo has said. "CVS Health has ...
(Date:9/19/2014)... 19, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ... received and approved all parts required to build ... begun to manufacture the new PCT-based instrument system.  ... ready for shipment by mid-October and that additional ... a rate of about one per week thereafter.  ...
(Date:9/19/2014)... MINNEAPOLIS and ORLANDO, Fla. ... data supporting Inspire therapy continues to grow, with the ... paper published on-line in Otolaryngology – Head ... therapy causes a worsening of both objective and subjective ... to directly attribute Inspire therapy for the reduction in ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
(Date:9/21/2014)... Faculty and staff at Garrison Forest School ... Owings Mills, Md., kicked off the academic year by taking ... is the first independent school to receive the bands— which ... sleep patterns— as part of a pilot program with ... specialty chain. The Vivofit bands are just one tool in ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 According to latest ... the highest birth rate since 1966 (10.5 births per 1,000 ... their early 40s has risen steadily by 2 percent per ... births to women aged 50 and over) also rose, the ... there were more than nine times as many first births ...
(Date:9/20/2014)... iFitDress.com, a well-known wedding dress manufacturer and retailer, has unveiled ... addition, the company has launched a special offer on the ... benefit all of its big fans. Worldwide people can buy ... Along with beautiful party dresses, the company also offers many ... new sexy short prom outfits and purple homecoming gowns online; ...
(Date:9/20/2014)... 2014 Diabetes Protocol , a ... is helping thousands of people learn how to naturally ... pills, or prescriptions has caught the attention of Shane ... currently tens of millions of people in the U.S. ... 2 diabetes, and unfortunately, big pharma makes a killing ...
(Date:9/20/2014)... 6 Minutes to Skinny , a fat loss ... is showing men and women of all ages how they ... using simple 6-minute exercises and easy-to-follow lifestyle tips daily, has ... , “When it comes to losing body fat, unfortunately ... all people,” reports Michaels. “Metabolism plays a big role in ...
Breaking Medicine News(10 mins):Health News:Garrison Forest School Leader in Independent School Wellness Programs 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Beautiful Party Dresses For Autumn Unveiled By iFitDress.com 2Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2Health News:6 Minutes to Skinny: Review Exposes Craig Ballantyne’s Method to Jump Starting the Metabolism and Blasting Away Body Fat in Just 6 Minutes Per Day 2
... Konica Minolta Sensing Americas,Inc. (KMSA), the ... color,light and shape, announces the launch of ... product used in combination with Konica Minolta,s,portable ... simultaneously with a numerical display of the ...
... By playing it safe and using a two-pronged attack, a ... tested by an international team of researchers led by the ... similar to components of viruses and in this way alerts ... against cancer cells in this process. At the same time, ...
... Nurses Association to Ask Voters ... to Think of Health Care, TRENTON, N.J., Nov. 1 ... Ladies have,joined forces to ask the state,s public policy makers to ... and federal level. The First Ladies,joined the newest members of the ...
... , , SATURDAY, Nov. 1 (HealthDay News) -- Personalized treatment ... a UCLA study of almost 1,500 patients that identified ... to be treated accordingly. , The UCLA team said ... to be changed. , "We have shown that not ...
... the #1 position among detox procedures for opiate addiction, there is a ... , ... Palm Beach, FL (PRWEB) November 1, 2008 -- The primary ... as Meditox of Palm Beach that offer it? The drug can ...
... of nearly 1,500 patients treated for kidney cancer at ... aggressive, tailored treatment approach results in better survival rates ... and need to be treated accordingly. , The one-size-fits-all ... changed based on the results of the study, the ...
Cached Medicine News:Health News:Konica Minolta Sensing Americas Announces the Launch of the CM-SA Skin Analysis Software 2Health News:Substance tackles skin cancer from 2 sides 2Health News:On Weekend Before the Election, New Jersey's First Ladies Speak Out for Healthcare 2Health News:On Weekend Before the Election, New Jersey's First Ladies Speak Out for Healthcare 3Health News:Tailored Treatment Boosts Kidney Cancer Survival 2Health News:Suboxone Fast Passing Methadone As Preferred Method Of Treatment For Opiate Detox 2Health News:Landmark UCLA study finds aggresive, personalized treatment increases kidney cancer patient survival 2Health News:Landmark UCLA study finds aggresive, personalized treatment increases kidney cancer patient survival 3
... LH Ovulation Predicting Test is a qualitative ... Hormone (hLH) in human urine to predict ... by the elevation of human luteinizing hormone ... period starts, hLH has a brief, significant ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... The Shandon Varistain 24-4 ... stainer designed to offer simplicity ... cytology staining applications. It is ... load and continuous throughput. ...
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: